Abstract
Objective: To describe the relationship between advanced glycation and the development of cardiovascular diseases in patients with type 2 Diabetes Mellitus (T2DM), emphasizing pathophysiological mechanisms, biomarkers, assessment methods, and prevention and treatment strategies. Methods: This is an integrative literature review conducted using the MEDLINE/PubMed, LILACS, SciELO, Embase, and Scopus databases. Studies published preferably between 2020 and 2025 in Portuguese, English, or Spanish were included. Study selection was performed independently by two reviewers, followed by a descriptive analysis of the evidence. Results/Discussion: The evidence demonstrates that advanced glycation end products (AGEs) promote inflammation, oxidative stress, endothelial dysfunction, and vascular remodeling, primarily through activation of the AGE–RAGE axis, thereby contributing to atherosclerosis and increasing cardiovascular risk. Biomarkers such as Nε-carboxymethyl lysine (CML), methylglyoxal-derived hydroimidazolone-1 (MG-H1), soluble receptor for advanced glycation end products (sRAGE), the hemoglobin glycation index (HGI), and skin autofluorescence have shown potential for cardiovascular risk stratification. However, their clinical application remains limited by the lack of standardized assessment methods and the predominance of observational studies. Final considerations: Advanced glycation is an important mechanism associated with increased cardiovascular risk in patients with T2DM. However, prospective studies and standardized protocols are still needed to validate the clinical application of these biomarkers and to expand their use in the prevention and management of cardiovascular complications.
References
1. BANSAL S, et al. Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes. World Journal of Diabetes, 2023; 14(8): 1146-1162.
2. BENJAMIN EJ, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA, 1994; 271(11): 840-844.
3. BOERSMA HE, et al. Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes. BMC Endocrine Disorders, 2021; 21(1): 14.
4. CHOI LS, et al. Skin accumulation of advanced glycation end products and cardiovascular risk in Korean patients with type 2 diabetes mellitus. Heliyon, 2022; 8(6): e09571.
5. DE LA CRUZ-ARES S, et al. Endothelial dysfunction and advanced glycation end products in patients with newly diagnosed versus established diabetes: From the CORDIOPREV Study. Nutrients, 2020; 12(1):238..
6. DE VOS LC, et al. Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014; 34(4):933-8.
7. DINESH SHAH A, et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1.9 million people. The Lancet, 2015; 385: S86.
8. DUQUE A, et al. Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications. World Journal of Diabetes, 2021; 12(6): 855-867.
9. GIGLIO RV, et al. Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2021; 1867(8): 166148.
10. GUPTA A, et al. Soluble receptor for advanced glycation end products and its role in cardiovascular risk assessment in hyperglycemia - A study in North India. Journal of Family Medicine and Primary Care, 2025; 14(4): 1325-1332.
11. HUXLEY RR, et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. The American Journal of Cardiology, 2011; 108(1): 56-62.
12. KADOWAKI T, et al. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan. Diabetes, Obesity and Metabolism, 2022; 24(12): 2283-2296.
13. KANEKO H, et al. Fasting plasma glucose and subsequent cardiovascular disease among young adults: Analysis of a nationwide epidemiological database. Atherosclerosis, 2021.
14. KIM Y. Blood and Tissue Advanced Glycation End Products as Determinants of Cardiometabolic Disorders Focusing on Human Studies. Nutrients, 2023; 15(8): 2002.
15. LEE J, et al. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. Nutrients, 2022; 14(15): 3086.
16. LI LY, et al. High serum levels of N-epsilon-carboxymethyllysine are associated with poor coronary collateralization in type 2 diabetic patients with chronic total occlusion of coronary artery. BMC Cardiovascular Disorders, 2022; 22(1): 282.
17. LIN Z, et al. Hemoglobin glycation index and cardiovascular outcomes in patients with diabetes and coronary artery disease: insights from a large cohort study. Nutrition & Diabetes, 2024; 14(1): 69.
18. LINKENS AMA, et al. Habitual Intake of Dietary Advanced Glycation End Products Is Not Associated with Arterial Stiffness of the Aorta and Carotid Artery in Adults: The Maastricht Study. The Journal of Nutrition, 2021; 151(7): 1886-1893.
19. MOVAHED MR, et al. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. International Journal of Cardiology, 2005; 105(3): 315-318.
20. NAKAMURA T, et al. Continuous low serum levels of advanced glycation end products and low risk of cardiovascular disease in patients with poorly controlled type 2 diabetes. Cardiovascular Diabetology, 2023; 22(1): 147.
21. OMACHI T, et al. Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study. Diabetes Therapy, 2024; 15(1): 111-126.
22. PLANAS A, et al. Advanced Glycations End Products in the Skin as Biomarkers of Cardiovascular Risk in Type 2 Diabetes. International Journal of Molecular Sciences, 2022; 23(11): 6234.
23. PINTO RS, et al. Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease. International Journal of Molecular Sciences, 2022; 23(5): 2404.
24. RAGAZZI E, et al. Anti-diabetic combination therapy with pioglitazone or glimepiride added to metformin on the AGE-RAGE axis: a randomized prospective study. Frontiers in Endocrinology, 2023; 14: 1163554.
25. REUREAN-PINTILEI D, et al. Associations between Skin Autofluorescence Levels with Cardiovascular Risk and Diabetes Complications in Patients with Type 2 Diabetes. Biomedicines, 2024; 12(4): 890.
26. REUREAN-PINTILEI D, et al. Skin Autofluorescence as a Potential Adjunctive Marker for Cardiovascular Risk Assessment in Type 2 Diabetes: A Systematic Review. International Journal of Molecular Sciences, 2024; 25(7): 3889.
27. STIRBAN A, et al. Acute macrovascular dysfunction in patients with type 2 diabetes induced by ingestion of advanced glycated β-lactoglobulins. Diabetes Care, 2013; 36(5): 1278-1282.
28. VAN DER BRUGGEN MM, et al. Plasma Reactive Dicarbonyls Are Not Independently Associated With Arterial Stiffness: The Maastricht Study. American Journal of Hypertension, 2025; 38(10): 777-787.
29. VEKIC J, et al. The Role of Advanced Glycation End Products on Dyslipidemia. Metabolites, 2023; 13(1): 77.
30. WANG Y, et al. Association between hemoglobin glycation index and 5-year major adverse cardiovascular events: the REACTION cohort study. Chinese Medical Journal, 2023; 136(20): 2468-2475.
31. WU C, et al. Glycemic variability of glycated hemoglobin in patients with type 2 diabetes mellitus and the risk of cardiovascular diseases: a latest systematic review and meta-analysis. Frontiers in Endocrinology, 2025; 16: 1698360.
32. XU S, et al. The hemoglobin glycation index predicts the risk of adverse cardiovascular events in coronary heart disease patients with type 2 diabetes mellitus. Frontiers in Cardiovascular Medicine, 2022; 9: 992252.
33. YOZGATLI K, et al. Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in type 2 diabetes mellitus. Diabetic Medicine, 2018; 35(9), 1242-1248.
